Adherence to liraglutide among individuals with overweight and obesity: Patient characteristics and clinical measures
Authors' conclusion
Only 15.1% of study participants exhibited high adherence to treatment (PDC ≥80%) after 6 months of follow-up. Further research is needed to explore approaches to enhance adherence to liraglutide, including strategies to educate and support patients in their efforts to achieve and maintain weight loss with the use of this drug.
Study context
- Population
- Patients with overweight or obesity treated with liraglutide, 2019–2022; 78.1% female, mean age 46 ± 12 years
- Participants
- 1,890 patients
- Outcome
- Treatment adherence by proportion of days covered (PDC); PDC ≥80% = high adherence
- Follow-up
- 6-month follow-up
Main finding
As reported in the abstract
Low adherence to liraglutide (PDC <80%) · end of 6-month follow-up
Low adherence
84.9%
High adherence (proportion of days covered (PDC) ≥80%)
15.1%
Observational data: associations, not effects.
Further findings
Determinants of high adherence
- Age (adherence improved with age): OR 1.013, CI 1.001-1.025, p = 0.04
- Significant weight loss during treatment: OR 1.251, CI 1.167-1.341, p < 0.001
- Higher socioeconomic status: OR 1.906, CI 1.091-3.328, p = 0.023
- Smoking (greater adherence in non-smokers): OR 0.725, CI 0.528-0.996, p = 0.047
Original publication
Adherence to liraglutide among individuals with overweight and obesity: Patient characteristics and clinical measures. Diabetes Obes Metab. Published 19 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →